Dataset Information


SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.

ABSTRACT: Epigenetic regulations play crucial roles in leukemogenesis and leukemia progression. SUV39H1 is the dominant H3K9 methyltransferase in the hematopoietic system, and its expression declines with aging. However, the role of SUV39H1 via its-mediated repressive modification H3K9me3 in leukemogenesis/leukemia progression remains to be explored. We found that SUV39H1 was down-regulated in a variety of leukemias, including MLL-r AML, as compared with normal individuals. Decreased levels of Suv39h1 expression and genomic H3K9me3 occupancy were observed in LSCs from MLL-r-induced AML mouse models in comparison with that of hematopoietic stem/progenitor cells. Suv39h1 overexpression increased leukemia latency and decreased the frequency of LSCs in MLL-r AML mouse models, while Suv39h1 knockdown accelerated disease progression with increased number of LSCs. Increased Suv39h1 expression led to the inactivation of Hoxb13 and Six1, as well as reversion of Hoxa9/Meis1 downstream target genes, which in turn decelerated leukemia progression. Interestingly, Hoxb13 expression is up-regulated in MLL-AF9-induced AML cells, while knockdown of Hoxb13 in MLL-AF9 leukemic cells significantly prolonged the survival of leukemic mice with reduced LSC frequencies. Our data revealed that SUV39H1 functions as a tumor suppressor in MLL-AF9-induced AML progression. These findings provide the direct link of SUV39H1 to AML development and progression.


PROVIDER: S-EPMC7728597 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5418093 | BioStudies
2019-01-01 | S-EPMC6609858 | BioStudies
2014-01-01 | S-EPMC3959278 | BioStudies
1000-01-01 | S-EPMC3172801 | BioStudies
2020-01-01 | S-EPMC7313134 | BioStudies
1000-01-01 | S-EPMC3362364 | BioStudies
1000-01-01 | S-EPMC6354558 | BioStudies
2015-01-01 | S-EPMC4592469 | BioStudies
2019-01-01 | S-EPMC6602096 | BioStudies
2020-01-01 | S-EPMC7026046 | BioStudies